Compare Humana Inc (HUM) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Upstart Holdings Inc — how do they compare? Humana Inc trades at $374.6 (market cap $46.31B), while Upstart Holdings Inc trades at $29.15 (market cap $2.94B). The key difference: Humana Inc is far larger — about 15.8× Upstart Holdings Inc's market cap, and Humana Inc pays a 0.92% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| HUM | UPST | |
|---|---|---|
Market Cap | $46.31B | $2.94B |
Sector | Health | Financials |
52-Week High | $409.42 | $73.76 |
52-Week Low | $163.67 | $24.22 |
Enterprise Value | $53.67B | — |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Upstart (UPST) trades at $31.09, up 4.64% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth of 42% year-over-year and a return to GAAP profitability, with loan originations surging 50%. However, it has missed EPS expectations for three consecutive quarters. The stock is supported by a consensus analyst price target of $47.20, implying significant upside, but faces headwinds from high interest rates and competitive pressures.
The outlook is mixed: strong loan growth and AI-driven underwriting improvements offer growth potential, but recent earnings misses, a high P/E ratio of 59.79, and negative operating cash flow in 2025 pose risks. Investor sentiment is cautiously optimistic, with 45% of analysts rating it a Buy, though volatility from macroeconomic factors remains a key concern for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
